Meanwhile, investors await key clinical data.
ApexOnco Front Page
Recent articles
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
The ROR1 data are sketchy, and lung toxicity clouds prospects.
A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
Meanwhile, Bristol’s other competition in this disease looks set to come from China.